Skip to main content

Advertisement

SpringerLink
Log in

PYCR1 promotes bladder cancer by affecting the Akt/Wnt/β-catenin signaling

  • Published:
Journal of Bioenergetics and Biomembranes Aims and scope Submit manuscript

Abstract

Pyrroline-5-carboxylate reductase 1 (PYCR1) plays a significant role in the malignant progression of various cancers. However, the role of PYCR1 in bladder cancer has not been well studied. This study was performed to evaluate the potential relevance of PYCR1 in bladder cancer. Our data revealed that PYCR1 expression was increased in bladder cancer tissues, and increased expression of PYCR1 was predictive of decreased survival rates. In bladder cancer cell lines, knockdown of PYCR1 caused significantly retarded cell growth and invasion, while PYCR1 overexpression accelerated cellular proliferation and invasion. Moreover, PYCR1 knockdown decreased levels of phosphorylated Akt, and enhanced activation of Wnt/β-catenin signaling. Akt inhibition markedly abrogated of PYCR1 overexpression-mediated activation of Wnt/β-catenin signaling. In addition, overexpression of β-catenin partially reversed PYCR1 knockdown-mediated tumor suppression. Notably, PYCR1 knockdown significantly impeded tumor formation and growth in bladder cancer cells in vivo. In conclusion, these data demonstrate that PYCR1 is highly expressed in bladder cancer and knockdown of PYCR1 exerts a remarkable inhibitory effect on tumor formation via downregulation of Akt/Wnt/β-catenin signaling. Our study suggests a potential role for PYCR1 in promoting bladder cancer progression and indicates that PYCR1 may be utilized as an attractive and promising anticancer target for treatment of bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Data availability

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  • Adams E, Frank L (1980) Metabolism of proline and the hydroxyprolines. Annu Rev Biochem 49:1005–1061

    Article  CAS  Google Scholar 

  • Berdik C (2017) Unlocking bladder cancer. Nature 551:S34–S35

    Article  CAS  Google Scholar 

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424

    Article  Google Scholar 

  • Cai F, Miao Y, Liu C, Wu T, Shen S, Su X, Shi Y (2018) Pyrroline-5-carboxylate reductase 1 promotes proliferation and inhibits apoptosis in non-small cell lung cancer. Oncol Lett 15:731–740

    PubMed  Google Scholar 

  • Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785–789

    Article  CAS  Google Scholar 

  • De Ingeniis J, Ratnikov B, Richardson AD, Scott DA, Aza-Blanc P, De SK, Kazanov M, Pellecchia M, Ronai Z, Osterman AL, Smith JW (2012) Functional specialization in proline biosynthesis of melanoma. PLoS One 7:e45190

    Article  Google Scholar 

  • Ding J, Kuo ML, Su L, Xue L, Luh F, Zhang H, Wang J, Lin TG, Zhang K, Chu P, Zheng S, Liu X, Yen Y (2017) Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers. Carcinogenesis 38:519–531

    Article  CAS  Google Scholar 

  • Du S, Zhang P, Ren W, Yang F, Du C (2020) Circ-ZNF609 accelerates the radioresistance of prostate cancer cells by promoting the glycolytic metabolism through miR-501-3p/HK2 axis. Cancer Manag Res 12:7487–7499

    Article  Google Scholar 

  • Duchartre Y, Kim YM, Kahn M (2016) The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol 99:141–149

    Article  Google Scholar 

  • Gao Y, Luo L, Xie Y, Zhao Y, Yao J, Liu X (2020) PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma. Mol Carcinog 59:503–511

    Article  CAS  Google Scholar 

  • Garg M, Maurya N (2019) WNT/beta-catenin signaling in urothelial carcinoma of bladder. World J Nephrol 8:83–94

    Article  Google Scholar 

  • Guo L, Cui C, Zhang K, Wang J, Wang Y, Lu Y, Chen K, Yuan J, Xiao G, Tang B, Sun Y, Wu C (2019) Kindlin-2 links mechano-environment to proline synthesis and tumor growth. Nat Commun 10:845

    Article  Google Scholar 

  • Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstrom PU, Choi W, Guo CC, Lotan Y, Kassouf W (2016) Bladder cancer. Lancet 388:2796–2810

    Article  Google Scholar 

  • McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, Siefker-Radtke A, Dinney C, Czerniak B (2010) Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol Oncol 28:429–440

    Article  CAS  Google Scholar 

  • Mosimann C, Hausmann G, Basler K (2009) Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol 10:276–286

    Article  CAS  Google Scholar 

  • Nakamura T, Hamada F, Ishidate T, Anai K, Kawahara K, Toyoshima K, Akiyama T (1998) Axin, an inhibitor of the Wnt signalling pathway, interacts with beta-catenin, GSK-3beta and APC and reduces the beta-catenin level. Genes Cells 3:395–403

    Article  CAS  Google Scholar 

  • Niehrs C (2012) The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol 13:767–779

    Article  CAS  Google Scholar 

  • Pang C, Guan Y, Li H, Chen W, Zhu G (2016) Urologic cancer in China. Jpn J Clin Oncol 46:497–501

    Article  Google Scholar 

  • Reversade B, Escande-Beillard N, Dimopoulou A, Fischer B, Chng SC, Li Y, Shboul M, Tham PY, Kayserili H, Al-Gazali L, Shahwan M, Brancati F, Lee H, O'Connor BD, Schmidt-von Kegler M, Merriman B, Nelson SF, Masri A, Alkazaleh F, Guerra D, Ferrari P, Nanda A, Rajab A, Markie D, Gray M, Nelson J, Grix A, Sommer A, Savarirayan R, Janecke AR, Steichen E, Sillence D, Hausser I, Budde B, Nurnberg G, Nurnberg P, Seemann P, Kunkel D, Zambruno G, Dallapiccola B, Schuelke M, Robertson S, Hamamy H, Wollnik B, Van Maldergem L, Mundlos S, Kornak U (2009) Mutations in PYCR1 cause cutis laxa with progeroid features. Nat Genet 41:1016–1021

    Article  CAS  Google Scholar 

  • Sathe A, Nawroth R (2018) Targeting the PI3K/AKT/mTOR pathway in bladder cancer. Methods Mol Biol 1655:335–350

    Article  CAS  Google Scholar 

  • Wang D, Wang L, Zhang Y, Yan Z, Liu L, Chen G (2019) PYCR1 promotes the progression of non-small-cell lung cancer under the negative regulation of miR-488. Biomed Pharmacother 111:588–595

    Article  CAS  Google Scholar 

  • Wang QL, Liu L (2019) PYCR1 is associated with papillary renal cell carcinoma progression. Open Med (Wars) 14:586–592

    Article  CAS  Google Scholar 

  • Weijin F, Zhibin X, Shengfeng Z, Xiaoli Y, Qijian D, Jiayi L, Qiumei L, Yilong C, Hua M, Deyun L, Jiwen C (2019) The clinical significance of PYCR1 expression in renal cell carcinoma. Medicine 98:e16384

    Article  Google Scholar 

  • Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A (2014) EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 65:778–792

    Article  Google Scholar 

  • Yan K, Xu X, Wu T, Li J, Cao G, Li Y, Ji Z (2019) Knockdown of PYCR1 inhibits proliferation, drug resistance and EMT in colorectal cancer cells by regulating STAT3-mediated p38 MAPK and NF-kappaB signalling pathway. Biochem Biophys Res Commun 520:486–491

    Article  CAS  Google Scholar 

  • Yasuda T, Kaji Y, Agatsuma T, Niki T, Arisawa M, Shuto S, Ariga H, Iguchi-Ariga SM (2013) DJ-1 cooperates with PYCR1 in cell protection against oxidative stress. Biochem Biophys Res Commun 436:289–294

    Article  CAS  Google Scholar 

  • Ye Y, Wu Y, Wang J (2018) Pyrroline-5-carboxylate reductase 1 promotes cell proliferation via inhibiting apoptosis in human malignant melanoma. Cancer Manag Res 10:6399–6407

    Article  CAS  Google Scholar 

  • Zeng T, Zhu L, Liao M, Zhuo W, Yang S, Wu W, Wang D (2017) Knockdown of PYCR1 inhibits cell proliferation and colony formation via cell cycle arrest and apoptosis in prostate cancer. Med Oncol 34:27

    Article  Google Scholar 

  • Zhuang J, Song Y, Ye Y, He S, Ma X, Zhang M, Ni J, Wang J, Xia W (2019) PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer. J Transl Med 17:343

    Article  Google Scholar 

Download references

Code availability

Not applicable.

Author information

Authors and Affiliations

  1. Department of Urology, Shaanxi Provincial People’s Hospital, Xi’an, 710068, China

    Shuangkuan Du, Wei Ren, Jiancheng Zhou & Chun Du

  2. Department of Physical Examination, Shaanxi Provincial People’s Hospital, No.256 Youyi West Road, Xi’an, 710068, China

    Yongjie Sui

Authors
  1. Shuangkuan Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yongjie Sui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiancheng Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chun Du
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Shuangkuan Du designed the study, performed the experiments and drafted the manuscript. Yongjie Sui designed the study and revised the manuscript. Wei Ren performed the experiments. Jiancheng Zhou interpreted the data. Chun Du interpreted the data. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Yongjie Sui.

Ethics declarations

Ethics approval

Research was carried out with the approval of Ethics Committee of Shaanxi Provincial People’s Hospital and was conducted in accordance with the principles of the Helsinki Declaration. Animal experiments were performed with the approval of the Ethics Committee of Shaanxi Provincial People’s Hospital.

Consent to participate

All patients provided written informed consent with regard to tissue donation for the purpose of this study.

Consent for publication

All authors have approved for the publication of this manuscript.

Conflict of interest

The authors declare no conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(DOCX 497 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Du, S., Sui, Y., Ren, W. et al. PYCR1 promotes bladder cancer by affecting the Akt/Wnt/β-catenin signaling. J Bioenerg Biomembr 53, 247–258 (2021). https://doi.org/10.1007/s10863-021-09887-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10863-021-09887-3

Keywords

Search

Navigation